Where Do Cures Reside? Morrie Ruffin and Michael Werner of the Alliance for Regenerative Medicine Think the Answer Is in Regenerative Medicine Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 08 January 2015 18:07
The practice of medicine is being transformed. The journey has been arduous, but revolutionary stem cell, gene and immunocellular therapies are rapidly moving toward pivotal milestones—and investors in the space should strap in for a rewarding joy ride.
Read more...
 
Q&A: Actinium Pharmaceuticals Inc. CEO Eyes Orphan Drug Application for Flagship Drug Print E-mail
By M.E.Garza   
Wednesday, 07 January 2015 00:00
Actinium Pharmaceuticals Inc. a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers announced last month that the US Food and Drug Administration (FDA) had granted orphan-drug designation for Actimab-A, an alpha radiolabeled antibody being developed for newly diagnosed AML in patients over the age of 60.
Read more...
 
Pluristem’s Immunotherapy Breakthrough Could Fast-Track GvHD Studies under Japanese Legislation Print E-mail
By Sharon di Stefano   
Friday, 02 January 2015 16:20
With data in hand that shows evidence its PLX cell therapy produces an immune response, Pluristem Therapeutics (PSTI:NASDAQ) enters the exploding area of immunotherapy, or treating disease via manipulation of the human immune system, and joins the ranks of its larger pharmaceutical counterparts in an industry estimated at $35 billion with fast growth expected in the next seven to eight years.
Read more...
 
Will Biotech Fire on All Cylinders in 2015? Print E-mail
By Tracy Salcedo-Chourré of The Life Sciences Report   
Tuesday, 30 December 2014 21:13
Making predictions for the New Year may feel as productive as peering into a crystal ball. But in the life sciences, hard science and long experience back prognostication.
Read more...
 
Cell Therapy 2015: With Maturity Comes Promise Print E-mail
By Staff and Wire Reports   
Tuesday, 23 December 2014 22:33
A number of new and innovative medical paradigms are being explored by companies in the life sciences sector, with one of the front-runners being cell therapy—a disruptive technology that has, in the past few years, progressed out of preclinical studies and into clinical development.
Read more...
 
Doug Loe: Canada Has Earned Its Spot in the Biotech All-Star Team Photo Print E-mail
By Staff and Wire Reports   
Friday, 19 December 2014 08:49
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada.
Read more...
 
When Considering Cell Therapy Investments - Not All Cells Are the Same Q&A with Zami Aberman, Pluristem Therapeutics Print E-mail
By M.E.Garza   
Wednesday, 17 December 2014 19:54
BioMedReports.com’s editor, M.E. Garza, spoke with Pluristem CEO, Zami Aberman, a leading developer of placenta-based cell therapy products, regarding clear differentiators between cell therapies and why the cell manufacturing process is key. 
Read more...
 
Wedbush Securities' David Nierengarten on Genetic Cures for Disease: Impossible Dream Come True? Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 11 December 2014 13:23
  Clinicians like to speak in terms of "managing" disease. That term of art is an admission that, in most cases, they can't cure the serious problems confronting patients.
Read more...
 
Brinson Patrick's Christopher S. James: All Catalysts Are Not Created Equal Print E-mail
By George S. Mack of The Life Sciences Report   
Friday, 05 December 2014 08:56
Why do some good-news milestones cause stocks to languish, or even fall? Neurosurgeon Christopher James, managing director and senior biotechnology analyst at Brinson Patrick Securities, performs due diligence on stocks, in part, by connecting his clinical experience to the readiness of physicians and patients to adopt new therapies.
Read more...
 
Biotech Watchlist Update: Small-Cap Biotechs Struggle to Rebound Print E-mail
By Josh Gee   
Wednesday, 19 November 2014 09:56
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 8 of 56

Newsletter